메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색

논문 기본 정보

자료유형
학술저널
저자정보
Cheal Wung Huh (Department of Internal Medicine, Yongin Severance Hospital, Yonsei University College of Medicine, Seoul, Korea) Young Hoon You (Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea) Da Hyun Jung (Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea) Ra Ri Cha (Department of Internal Medicine, Gyeongsang National University Changwon Hospital, Changwon, Korea) Yeon Ji Kim (Department of Internal Medicine, Yongin Severance Hospital, Yonsei University College of Medicine, Seoul, Korea) Kyoungwon Jung (Department of Internal Medicine, Kosin University College of Medicine, Busan, Korea) Kyung Ho Song (CHA University, Ilsan Medical Center, Ilsan, Gyeonggi-do, Korea) Ki Bae Bang (Department of Internal Medicine, Dankook University College of Medicine, Cheonan, Chungcheongnam-do, Korea) Chung Hyun Tae (College of Medicine, Ewha Womans University, Seoul, Korea) Soo In Choi (Inje University Sanggye Paik Hospital, Inje University College of Medicine, Seoul, Korea)
저널정보
대한소화관운동학회(현 대한소화기능성질환.운동학회) Journal of Neurogastroenterology and Motility (JNM) Journal of Neurogastroenterology and Motility (JNM) Vol.30 No.3
발행연도
2024.7
수록면
313 - 321 (9page)
DOI
10.5056/jnm23150

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색

초록· 키워드

오류제보하기
Background/AimsAcid-suppressive drugs, such as proton pump inhibitors (PPIs), are treatment options for functional dyspepsia (FD). However, the efficacy of potassium-competitive acid blockers (P-CABs) in treating FD has not yet been established. This prospective multicenter clinical trial-based study aimed to assess the efficacy and safety of tegoprazan as a P-CAB treatment in patients with FD. MethodsFD was diagnosed using the Rome IV criteria. All patients received tegoprazan 50 mg once daily for 8 weeks. Dyspeptic symptoms were assessed using a dyspepsia symptom questionnaire (5-point Likert scale, Nepean Dyspepsia Index-Korean [NDI-K], and gastroesophageal reflux disease–health-related quality of life [GERD-HRQL]). The main outcome was satisfactory symptom relief rates at 8 weeks. ResultsIn this study, from the initial screening of 209 patients, 173 were included in the per-protocol set analysis. Satisfactory symptom relief rates at 8 and 4 weeks were 86.7% and 74.6%, respectively. In addition, the NDI-K and GERD-HRQL scores significantly improved at 8 and 4 weeks compared with the baseline scores. The efficacy of tegoprazan was not influenced by the FD subtype or Helicobacter pylori status. In patients with overlapping FD and GERD, there was a greater improvement in the NDI-K and GERD-HRQL scores than in patients with FD symptoms only. No serious drug-related adverse events occurred during this study. ConclusionTegoprazan (50 mg) administered once daily provided satisfactory symptom relief for FD.

목차

등록된 정보가 없습니다.

참고문헌 (0)

참고문헌 신청

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

최근 본 자료

전체보기

댓글(0)

0